^
Association details:
| Biomarker: | BCR-ABL1 T315I |
|---|---|
| Cancer: | Leukemia |
| Drug: | Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor) + Scemblix (asciminib) (Bcr-abl tyrosine kinase inhibitor, STAMP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combining the Allosteric ABL1 Inhibitor Asciminib (ABL001) with Ponatinib Suppresses Emergence of and Restores Efficacy Against Highly Resistant BCR-ABL1 Compound Mutants
Published date:
11/06/2019
Excerpt:
Additionally, the combination of asciminib with ponatinib resulted in suppression of T315I-inclusive compound mutant resistant clones using in vitro mutagenesis screens and significantly prolonged survival compared to either single agent in an in vivo T315I-inclusive compound mutant mouse xenograft model.
DOI:
https://doi.org/10.1182/blood-2019-131781
